% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Minges:299478,
author = {P. Minges$^*$ and M. Eder$^*$ and A.-C. Eder$^*$},
title = {{D}ual-{L}abeled {S}mall {P}eptides in {C}ancer {I}maging
and {F}luorescence-{G}uided {S}urgery: {P}rogress and
{F}uture {P}erspectives.},
journal = {Pharmaceuticals},
volume = {18},
number = {2},
issn = {1424-8247},
address = {Basel},
publisher = {MDPI},
reportid = {DKFZ-2025-00438},
pages = {143},
year = {2025},
abstract = {Dual-labeled compounds that combine radiolabeling and
fluorescence labeling represent a significant advancement in
precision oncology. Their clinical implementation enhances
patient care and outcomes by leveraging the high sensitivity
of radioimaging for tumor detection and taking advantage of
fluorescence-based optical visualization for surgical
guidance. Non-invasive radioimaging facilitates immediate
identification of both primary tumors and metastases, while
fluorescence imaging assists in decision-making during
surgery by offering a spatial distinction between malignant
and non-malignant tissue. These advancements hold promise
for enhancing patient outcomes and personalization of cancer
treatment. The development of dual-labeled molecular probes
targeting various cancer biomarkers is crucial in addressing
the heterogeneity inherent in cancer pathology and recent
studies had already demonstrated the impact of dual-labeled
compounds in surgical decision-making (NCT03699332,
NCT03407781). This review focuses on the development and
application of small dual-labeled peptides in the imaging
and treatment of various cancer types. It summarizes the
biomarkers targeted to date, tracing their development from
initial discovery to the latest advancements in
peptidomimetics. Through comprehensive analysis of recent
preclinical and clinical studies, the review demonstrates
the potential of these dual-labeled peptides to improve
tumor detection, localization, and resection. Additionally,
it highlights the evolving landscape of dual-modality
imaging, emphasizing its critical role in advancing
personalized and effective cancer therapy. This synthesis of
current research underscores the promise of dual-labeled
peptides in enhancing diagnostic accuracy and therapeutic
outcomes in oncology.},
subtyp = {Review Article},
keywords = {dual imaging (Other) / dual labeling (Other) /
dual-modality imaging (Other) / fluorescence labeling
(Other) / fluorescence-guided surgery (Other) / hybrid
molecule (Other) / isotope labeling (Other) /
peptidomimetics (Other) / small molecules (Other)},
cin = {FR01},
ddc = {610},
cid = {I:(DE-He78)FR01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40005958},
doi = {10.3390/ph18020143},
url = {https://inrepo02.dkfz.de/record/299478},
}